Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NRBO NeuroBo Pharmaceuticals

Watchlist
1.770
+0.040+2.31%
Close  12/09 16:00 ET
1.730
-0.040-2.26%
Post Mkt Price 12/09 19:58 ET
High
2.330
Open
1.970
Turnover
51.02M
Low
1.640
Pre Close
1.730
Volume
24.69M
Market Cap
11.51M
P/E(TTM)
Loss
52wk High
63.850
Shares
6.50M
P/E(Static)
Loss
52wk Low
1.130
Float Cap
11.20M
Bid/Ask %
95.00%
Historical High
16192.494
Shs Float
6.33M
Volume Ratio
9.87
Historical Low
1.130
Dividend TTM
--
Div Yield TTM
--
P/B
1.94
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
390.17%
Amplitude
39.88%
Avg Price
2.066
Lot Size
1
Float Cap
11.20M
Bid/Ask %
95.00%
Historical High
16192.494
Shs Float
6.33M
Volume Ratio
9.87
Historical Low
1.130
Dividend TTM
--
P/B
1.94
Dividend LFY
--
Turnover Ratio
390.17%
Amplitude
39.88%
Avg Price
2.066
Lot Size
1
Price Forecast

News

Comment

No Data

Company Overview More
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Listing Date: 08/05/2016
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist